| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We examined antimicrobial susceptibilities of Neisseria gonorrhoeae (total 2,787 clinical strains: 94 strains isolated from pharynx, 2,608 strains from urethra and 85 strains from cervix). Only ceftriaxone and spectinomycin have high antimicrobial activities against N. gonorrhoeae. Azithromycin is not recommended for treatment against gonococcal infections because the efficacy of azithromycin for gonococcal urethritis was decreased in Sendai. Moreover spectinomycin is not used to treat pharyngeal infection because of low tissue penetration. Therefore it is thought that ceftriaxone is effective to treat gonococcal pharyngeal infection from these results. In fact, ceftriaxone 1g single dose that is recommended in Japanese guideline have 51.48 hours of “Therapeutic time”. It is thought that ceftriaxone 1g single dose is effective to treat gonococcal pharyngeal infection because therapeutic time of this dose is over 30 hours that is >95% expected cure rate in pharyngeal infection.
|
